Boston Scientific Corporation announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan.
The Company plans to launch the product after reimbursement approval is granted.
“The approval of the TAXUS Express2 stent is an important event for the treatment of cardiovascular disease in Japan,” said Jim Tobin, President and Chief Executive Officer of Boston Scientific. “We are pleased to provide Japanese physicians with this proven technology, which will help improve the quality of life for so many patients.”
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.